Litcius/Paper detail

Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC

James E. Frampton

2022Targeted Oncology11 citationsDOI

Topics & Concepts

OsimertinibMedicineOncologyInternal medicineAdjuvantLung cancerPopulationAdjuvant therapyEpidermal growth factor receptorStage (stratigraphy)ChemotherapyCancerErlotinibPaleontologyBiologyEnvironmental healthLung Cancer Treatments and MutationsGastric Cancer Management and OutcomesColorectal Cancer Treatments and Studies
Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC | Litcius